The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or -deferred multiple myeloma. The regimen reduced risk for disease progression or death by 43%.

negative serum and urine electrophoresis with immunofixation for monoclonal protein; normal IgG, IgA, and IgM levels; κ and λ FLC, troponin T, and NT-proBNP were not available; 24-hour urine ...

Daratumumab, hyaluronidase-fihj; 1800mg/30000units; per vial; soln for SC inj; preservative-free. Daratumumab binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing ...

Previous results on immunofixation electrophoresis (IFE) and quantitative free light chain (FLC) measurements have been conflicting. Patients and Methods: The purpose of this study was to compare ...

Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to afford that, last year she took the second option of a stem cell transplant.